Retrospective cohort study demonstrates safety and effectiveness of abrocitinib in atopic dermatitis, indicating its viability compared to other treatments.
Abrocitinib demonstrates real-world efficacy and safety in moderate-to-severe AD, including patients with inadequate responses to other dupilumab or JAK inhibitors, including those with prior exposure to biologics or other JAK inhibitors.
No takes yet. Share an insight, caveat, or question.
Gwag et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: